It is widely known that the arenavirus Lymphocytic choriomeningitis (LCM) poses a grave threat to both immunocompetent and immunodeficient individuals alike. We offer full development services for vaccines and therapeutic agents relating to LCM at our company.
Lymphocytic choriomeningitis virus (LCMV) is an Arenaviridae family zoonotic viral pathogen that is carried by rodents. In humans, this virus is contracted through the wastes or saliva of infected rodents. Following exposure to an infected person, the range of illness one can experience largely varies from no symptoms at all to extremely severe neurological symptoms such as encephalitis or meningitis. Immunocompromised people or expecting mothers are at heightened danger due to the associated fetal LCMV infection or teratogenesis.
Fig.1 Brain and ocular pathological features of lymphocytic choriomeningitis (LCM). (Tevaearai F., et al., 2022)
Recombinant LCMV Vaccines
It is relevant to the formation of immune responses that reduce the chances of getting a disease. An example is the preclinical studies which showed the generation of cytotoxic multifunctional CD8+ T cells and memory T cells because of the inflammation train that was caused by non-replicating recombinant LCMV (rLCMV) vectors, which are indeed important for viral clearance.
Vector-Based Vaccines
These are termed as vector vaccines because biotechnology exploits a harmless virus to act as a vector that carries parts of LCMV for immune response setup. Such vaccines may also be made by using altered or weakened forms of the viral strains. This includes the rLCMV vector that express model antigens which was demonstrated to be safe and effective in immunodeficient mice.
Antiviral Therapies
Some advances have been made in devising antiviral therapy for LCMV, predominantly because of the constant negative impacts faced in some populations. The general antiviral, Ribavirin, has been given but with only limited success. In contrast, pyrazinecarboxamide derivative favipiravir proved very beneficial in preclinical models because of its strong antiviral effects by means of survival and considerably reduced viral loads.
Immunotherapies
Immunotherapeutic efforts have also been directed against those specific monoclonal antibodies which neutralize at the same level as the virus. They are, for instance, meant to block some of the protective mechanisms which are normally utilized by the host to defend itself against LCMV. Human monoclonal antibodies that were developed against Lassa virus glycoproteins have been shown to cross-react with LCMV and thus may be of therapeutic value.
Our firm is strategically positioned to provide confidently LCM vaccines and advanced therapies development services owing to our experienced research group with a specialization in infectious medicine and access to state of the art technology platforms. To address your specific scientific research requirements, we customize solutions, analytical processes, and ensure timely project execution tracking to accelerate your scientific advancements. Some of our services include:
Infection route: intraperitoneal, intravenous, subcutaneous, footpad, or intracranial injections
The urgent need for effective vaccines and therapies against lymphocytic choriomeningitis is evident. Our company is committed to advancing the research and development of innovative solutions to combat this neglected viral infection. If you are interested in our services, please feel free to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
